Androgen News and Research

RSS

Cleveland Clinic researcher awarded grant to advance treatment of lethal prostate cancer

The Prostate Cancer Foundation has presented Nima Sharifi, M.D., Kendrick Family Endowed Chair for Prostate Cancer Research at Cleveland Clinic's Lerner Research Institute, a Challenge Award to advance the treatment of lethal prostate cancer. He is also co-investigator on a second Challenge Award that was also selected for funding.

23 Jan 2015

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.

16 Jan 2015

ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix, Inc., a leading provider of cloud-based healthcare analytics solutions, today announced that the Urology Department of the University of North Carolina School of Medicine is using its cloud-based RegistryMetrix analytics platform.

15 Jan 2015

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer.

8 Jan 2015

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women.

14 Dec 2014

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer.

12 Dec 2014

Endocrinologist examines benefits and harms of testosterone therapy

An article in the latest edition of Australian Prescriber looks at the prescribing of testosterone, often used for ‘male menopause’ symptoms such as reduced energy, poor concentration and increased body fat. Over the past decade there has been a steep rise in the amount of testosterone dispensed in Australia and globally.

4 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA.

3 Dec 2014

Exome sequencing refines 46,XY DSD diagnosis

Exome sequencing can identify a likely genetic cause of 46,XY disorders of sex development in about a third of cases, report researchers.

1 Dec 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms.

5 Nov 2014

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.

30 Oct 2014

New combination therapy shows promise in treating prostate cancer

Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness.

16 Oct 2014

Endocrine Society issues updated Clinical Practice Guideline on androgens in women

The Endocrine Society today issued a Clinical Practice Guideline (CPG) advising against the use of testosterone therapy in healthy women.

5 Oct 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014